This is because many primary care practices and the numerous commercial programs offering GLP-1s that have sprouted up in the past 12 months cannot offer the experienced teams of providers necessary to obtain the best weight loss results
GLP-1 medications (semaglutide, liraglutide) have no established direct mechanism affecting menstrual cycles or reproductive hormones
This effect is more pronounced in perimenopausal and postmenopausal women, where baseline estrogen levels are already declining
Low iron, B12, and electrolyte status may compound fatigue, especially if dietary intake becomes restrictive
In clinical applications, in addition to treating T2DM, metformin has been found to be effective in certain diseases, such as obesity, cardiovascular disease, IBD, and other inflammation-related diseases
Not covered by health insurance